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Abstract Subcutaneous injection of the tumor cell suspen-
sion is a simple and commonly used tool for studying tumor
development in vivo. However, subcutaneous models poorly
resemble tumor complexity due to the fast growth not
reflecting the natural course. Here, we describe an application
of the new spheroid-plug model to combine the simplicity of
subcutaneous injection with improved resemblance to natural
tumor progression. Spheroid-plug model relies on in vitro for-
mation of tumor spheroids, followed by injection of single
tumor spheroid subcutaneously in Matrigel matrix. In
spheroid-plug model, tumors grow slower in comparison to
tumors formed by injection of cell suspension as assessed by
3D ultrasonography (USG) and in vivo bioluminescence mea-
surements. The slower tumor growth rate in spheroid-plug
model is accompanied by reduced necrosis. The spheroid-
plug model ensures increased and more stable vascularization
of tumor than classical subcutaneous tumor model as demon-
strated by 3D USG Power Doppler examination. Flow cytom-
etry analysis showed that tumors formed from spheroids have
enhanced infiltration of endothelial cells as well as hemato-
poietic and progenitor cells with stem cell phenotype (c-Kit+
and Sca-1+). They also contain more tumor cells expressing
cancer stem cell marker CXCR4. Here, we show that
spheroid-plug model allows investigating efficiency of anti-
cancer drugs. Treatment of spheroid-plug tumors with known
antiangiogenic agent axitinib decreased their size and viabili-
ty. The antiangiogenic activity of axitinib was higher in
spheroid-plug model than in classical model. Our results indi-
cate that spheroid-plug model imitates natural tumor growth
and can become a valuable tool for cancer research.
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Introduction
New potential antitumor drugs have to be tested in preclinical
animal models before being introduced into clinical trials. An-
imal models have contributed to select efficient cytotoxic che-
motherapeutics and helped to explain some of the mechanisms
of tumor development [1, 2]. However, many drugs that
showed therapeutic effects in animals failed in clinical trials
[3–6]. This discrepancy indicates that preclinical animal
models require improvements to better reflect complexity of
tumor biology.
Among mouse tumor models, subcutaneous implants of tu-
mor cell lines, either syngeneic or human xenografts, became
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most popular in basic cancer research and in drug development
process [7, 8]. Subcutaneous (s.c.) models are of relatively low
cost and easy to reproduce with a variety of available mouse
and human tumor cell lines [7]. Nevertheless, although being
simple, the s.c. models possess drawbacks [7, 8]. Tumor cells
within s.c. implant do not interact with stroma of tissue of origin
and tend to grow fast [7], hindering the selection of appropriate
experimental end points of an experiment [7, 9], what is partic-
ularly limiting when tested drug requires long-term dosage.
These disadvantages triggered the development of novel
rodent tumor models, including orthotopic models [10],
carcinogen-induced tumors [11], and transgenic animal tumor
models [12]. Although they resolved some problems connect-
ed with s.c. implantation of tumor cell lines, these more so-
phisticated approaches possess other drawbacks. Orthotopic
models better reflect the tumor-stroma interactions, however,
often imply advanced surgical procedures, what reduces the
number of animals in experiment [7]. Carcinogen-induced
models improved our understanding about processes driving
cancerogenesis, but their high variability makes them rarely
used in drug testing [7]. Genetic mouse models are powerful
scientific tools in investigating mechanisms of tumor devel-
opment, although tumors arise at various time points and are
difficult to follow [8]. Additionally, genetic mouse models are
costly, what all together makes them not appropriate for drug
testing [7, 8]. Therefore, despite having limitations, the simple
s.c. implantation of tumor cell lines is often the first choice
method for investigating antitumor strategies. Thus, any im-
provement in making s.c. models better resembling tumor
complexity while sustaining their simplicity may refine cur-
rent cancer research [1].
We propose a modification of classical s.c. model. We take
advantages of 3D spheroid in vitro culture of tumor cells and
combine them with assets of in vivo s.c. model. In contrast to
classical approach, where cells are injected as single-cell sus-
pension, our model relies on injecting a single spheroid within
a Matrigel plug. In this study, we aimed to determine if
injecting the same number of tumor cells bymeans of classical
s.c. model or spheroid-plug model has any influence on tumor
development, angiogenesis, infiltration by host cells, and het-
erogeneity of tumor cells. We also examined both models in
evaluating the efficacy of known antiangiogenic drug axitinib.
Obtained results indicate that the spheroid-plug model better




All animal procedures and experiments were performed in
accordance with national and European legislations, after
approval by the First Local Ethical Committee on Animal
Testing at the Jagiellonian University in Krakow (approval
number 50/2012). We used C57BL/6JOlaHsd mice in the study.
Cell culture and spheroid formation
In the study, we used B16F10 melanoma and Lewis lung
carcinoma (LLC) murine cell lines that were modified to sta-
bly express luciferase (luc) and green fluorescent protein
(GFP). To obtain LLC-luc-GFP cell line, LLC cells were
transduced with retroviral vectors produced using pMCSV-
luciferase plasmid and then selected by hygromycin
(25 μg/ml). Subsequently, luciferase-expressing cells were
transduced by LeGO-G2 lentiviral vectors [13] (kindly pro-
vided by Prof. Boris Fehse) and double sorted for GFP+ cells
with MoFlo cell sorter (Beckman Coulter, Brea, CA, USA).
B16F10 cells were transduced with retroviral vectors pro-
duced using pBMN-eGFP-ires-luc plasmid and then double
sorted for GFP+ cells withMoFlo cell sorter. B16F10-luc-GFP
and LLC-luc-GFP cell lines were cultured in RPMI or DMEM
HG medium, respectively (Lonza, Walkersville, MD, USA),
supplemented with 10 % fetal bovine serum (FBS) (Biowest,
Nuaillé, France) and 1 % penicillin-streptomycin (10,000 u/
ml, Gibco, Invitrogen, Carlsbad, CA, USA).
Spheroids were formed by seeding 1,000 cells/well in
100 μl of medium with 0.25 % methylcellulose (R&D Sys-
tems, Minneapolis, USA) on 96-well non-adherent, rounded-
bottom plate (CELLSTAR, GreinerBio-One, Frickenhausen,
Germany) as described previously for endothelial cells [14].
Formation of spheroids was assessed after 48 h using phase
contrast microscopy (Eclipse Ti, Nikon, Tokyo, Japan), and
only spheroids with round shape were chosen for further ex-
periments. The diameter of spheroids was approximately
~250 μm, and the number of cells in single spheroid was
within 1,500–3,500 range.
Subcutaneous injection of spheroids in Matrigel
For implantation of tumor cells, mice were anesthetized with
intraperitoneal (i.p.) injection of Avertin aqueous solution (2,
2,2-tribromoethanol in tert-amyl alcohol, a dose of 0.25 mg/g
of body weight; Sigma-Aldrich, St. Louis, MO, USA) and
shaved.
The spheroid-plugmodel relies on injection of single tumor
spheroid in the Matrigel matrix. We suspend a single spheroid
in cold liquid Matrigel that upon subcutaneous injection po-
lymerizes providing a single spheroid trapped within Matrigel
plug (Fig. 1). To avoid losing or disintegrating spheroid during
this procedure, we used the following protocol. First, 250 μl
of cold liquid growth factor-reduced Matrigel (BD Biosci-
ence, San Jose, CA, USA) was aliquoted into precooled 1.5-
ml Eppendorf tubes. Next, ~200 μl of air was drawn into the
precooled 1-ml syringe (BD Plastipak, Franklin Lakes, NJ,
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USA) — this helps to reduce dead volume of syringe and
needle. Then, half of the Matrigel volume (~125 μl) was
drawn into the syringe without mounted needle. In the next
step, the syringe was put into the well with the spheroid, and
the spheroid was collected in ~25 μl of medium. After ensur-
ing that spheroid is not left in the plate (binoculars are helpful),
the rest of the Matrigel was drawn into the syringe, the
precooled 18-G needle (Kruuse, Langeskov, Denmark) was
mounted, and remaining air was removed. The Matrigel with
spheroid was slowly injected subcutaneously into abdominal
flank. Needle was removed after 2–3 min to let the Matrigel to
polymerize and to avoid leakage. Two plugs per mice were
injected. Each plug was analyzed individually. We demon-
strated in vitro that transferring the spheroid according to such
procedure does not affect its structure (Supplemental Fig. S1).
Classical subcutaneous injection of tumor cells
For the classical method of subcutaneous injection of tu-
mor cell suspension, the cells were detached from culture
flasks with 0.25 % trypsin/EDTA solution and counted.
For a single injection, 1,500 cells were suspended in
250 μl of liquid Matrigel matrix. The number of 1,500
cells corresponds to the lowest range of cell number in
single spheroid (1,500–3,500). Therefore, injecting 1,500
cells in classical model ensures that potential differences
between tumor growth models are not due to lower num-
ber of cells injected within spheroid.
Treatment
Powder form of axitinib (Selleck Chemicals, Houston, TX
77054 USA) was dissolved in 0.5 % carboxymethyl cellulose
to form homogenous solution and stored in 4 °C. Dosing
started 7 days after tumor cell injection and lasted till the
end of experiment. Mice from treated group were adminis-
tered orally twice a day with a dose of 30 mg axitinib/kg of
body weight. Similarly, control group was administered with
corresponding volumes of 0.5 % carboxymethyl cellulose.
3D ultrasonography (3D-USG) analysis
3D-USG (VEVO 2100, MS550D transducer, VisualSonics,
Toronto, ON, Canada) allowed for monitoring tumor volume
along with vasculature content. Mice were shaved and anes-
thetized with isoflurane (1–2 % with air flow of 0.5 L/min)
(Baxter, Deerfield, IL, USA). For vasculature measurements,
Power Doppler mode was used with Doppler gain 35 dB,
dynamic range 35 dB, and wall filter in medium mode. Mea-
surements were conducted in three time points: 1, 7, and
14 days after the injection of tumor cells. The vascularization
was expressed as percentage of vascularization, what repre-
sents the percentage of pixels in a given area with positive
Power Doppler signal. Results were analyzed in 3D mode
using VEVO 2100 Software.
In vivo detection of bioluminescence
Tests were conducted along with 3D-USG analysis in the
same three time points, using In Vivo Imaging System
(IVIS) Lumina (PerkinElmer, Waltham, MA, USA). Twenty
minutes before imaging, mice were injected i.p. with 0.2 ml
luciferin (15 mg/ml, Promega GmbH, Mannheim, Germany).
Five minutes before measurement, animals were anesthetized
with isoflurane. Exposure time for bioluminescence measure-
ments was 60 s with medium binning mode. In case of over-
saturation of detected signal, the timewas shortened. Obtained
data are presented as average radiance [photon/s/cm2/sr]. This
unit is called further as radiance units (RU).
For detection of metastasis in organs, mice were injected
i.p. with luciferin 15 min before sacrifice. Next, lungs, liver,
and intestines were excised, and bioluminescence was mea-
sured with exposure of 60 s, binning mode. Mice with positive
bioluminescent signal in any of the organs were counted as
possessing metastases.
Flow cytometry analysis
Tumor plugs were dissected and divided into two parts: one
for flow cytometry and second for histological analysis. For
flow cytometry analysis, plug was chopped using a scalpel,
Fig. 1 Outline of the spheroid-
plug model. The spheroid-plug
model relies on in vitro formation
of tumor spheroid. Single spher-
oid is injected subcutaneously
within Matrigel matrix
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placed in 2-ml Eppendorf tube, and digested in 0.5 ml of
enzyme mix (37 °C, 1 h) which consisted of Liberase TM
3 U/ml (Roche, Indianapolis, IN, USA), hyaluronidase
25 μg/ml (Sigma-Aldrich, St. Louis, MO, USA), DNAse
25 μg/ml (Roche, Indianapolis, IN, USA), and dispase 3 U/
ml (Sigma-Aldrich, St. Louis, MO, USA). After 1 h, 0.5 ml of
FBS was added, and samples were placed on ice to stop the
reaction. Cell suspension was filtered through 70-μm strainer
(BD Bioscience, San Jose, CA, USA), centrifuged (600×g,
10 min, 4 °C), and stained in 2 % FBS in PBS for 20 min
on ice with antibodies listed in Supplemental Fig. S2. Flow
cytometry was performed using BD LSR II (BD Bioscience,
San Jose, CA, USA) with excitation lasers 405, 488, and
633 nm. Results were analyzed using FACS DIVA software
(BD Bioscience, San Jose, CA, USA) and FlowJo software
(Tree Star, USA).
Histological analysis
Dissected tumor plugs were kept overnight in freshly prepared
formalin solution and dehydrated in tissue processor (Shandon
Excelsior ES, Thermo Scientific, Kalamazoo,MI, USA) using
reagents provided by DiaPath (DiaPath, Martinengo, Italy).
Dehydrated plugs were embedded in paraffin, cut into
4-μm-thick sections on microtome (HM 355S, Thermo Sci-
entific, Kalamazoo, MI, USA), and stained with hematoxylin
and eosin (Sigma-Aldrich, St. Louis, MO, USA) in Varistain
Gemini automated slide stainer (Thermo Scientific, Kalama-
zoo, MI, USA), according to a standard protocol. Prepared
sections were analyzed under a microscope (Eclipse Ti,
Nikon, Tokyo, Japan). Pictures were taken using NIS-
Elements BR software. Content of necrotic tissue was
assessed using AxioVision 40 V 4.8.2 software (Carl Zeiss
Microscopy, Jena, Germany).
Statistical analysis
Statistical analysis and presentation of data were performed
with the use of GraphPad Prism 6 software (GraphPad Soft-
ware, San Diego, CA, USA). Obtained results are presented as
means±SEM. Statistical significance was analyzed using non-
paired Mann–Whitney test. If more than two groups of data
were analyzed with more than one variable, two-way ANOVA
with Bonferroni post-test was used, preceded by logarithmic
transformation in the case of log-normal distribution of values.
Results
Tumor growth is slower in spheroid-plug model
First, we compared the kinetics of tumor growth in classical
and spheroid-plug model using noninvasive 3D-USG. Size of
B16 tumors injected by classical method increased logarith-
mically (14.37±4.51-fold increase at day 14) (Fig. 2a). In
contrast, in spheroid-plug model, B16 tumor plugs did not
significantly change their size (1.07±0.12-fold increase)
(Fig. 2a). Consistently, LLC tumors injected by spheroid-
plug model were also smaller than tumors injected classically
(1.82±0.20- vs. 2.69±0.39-fold increase at day 14, p<0.01);
however, the difference between the models was much less
pronounced than in B16 tumors (Fig. 2a).
In addition to 3D-USG technique, we compared kinet-
ics of tumor growth by in vivo detection of biolumines-
cence (IVIS). Two-way ANOVA indicates that model ap-
plied for implantation of B16 cells influences the tumor
growth (p<0.01), with significantly faster increase in lu-
minescence in case of classical method (Fig. 2b). Howev-
er, at day 14, the IVIS signal intensity from B16 tumors in
spheroid-plug model was much higher than on the day 1
and similar to that in classical model (2.04±0.46×107 vs.
3.99±0.23×107 at day 14, NS) (Fig. 2b). Thus, at day 14,
the difference between models in tumor volumes was no-
tably higher (15.16-fold, Fig. 2a) than the difference in
IVIS signal (1.96-fold, Fig. 2b). Accordingly, in the case
of LLC tumors, we did not notice differences in IVIS
signal (Fig. 2b) between models (4.26±0.53×106 vs.
3.79±0.86×106), despite small but statistically significant
difference in LLC tumor volumes (Fig. 2a).
We concluded that spheroid-plug tumors grew slower
than tumors formed in classical model. However, mea-
surements of tumor volumes by 3D-USG were not
paralleled by detection of tumor cell-derived luminescence
detected by IVIS.
Tumors in spheroid model are less necrotic
In the next step, we investigated possible reasons for the
discrepancy between tumor volumes and IVIS signal in-
tensities. Because only viable cells are able to express
luciferase and produce detectable bioluminescence signal,
the inconsistency between tumor volumes and IVIS mea-
surements may indicate the presence of necrotic, not vi-
able areas within tumor. Indeed, histological analysis
using hematoxylin and eosin staining confirmed that
B16 and LLC tumors from spheroid-plug model had
smaller area of necrotic tissue than tumors from classical
method (B16 10.46±2.91 vs. 21.49±3.13 %, p<0.05;
LLC 17.95±5.06 vs. 34.26±3.06 %, p<0.05) (Fig. 3a).
Given that variable necrosis content results in discrep-
ancy between tumor volumes and IVIS signal, we pro-
posed that a ratio of tumor volume (measured, e.g., using
3D-USG) to the IVIS signal intensity from the tumor
(Fig. 3b) may be used to evaluate necrosis content within
tumors in quantitative and noninvasive manner. We dem-
onstrated that this parameter, named here the necrosis
2484 Tumor Biol. (2016) 37:2481–2496
factor (NF), correlates significantly with necrosis content
in all analyzed tumors estimated by histology (r=0.48,
p<0.0068, Spearman rang correlation) (Fig. 3b). The cal-
culated NF showed signif icant , consistent with
Fig. 2 Different kinetics of growth in spheroid-plug model and classical
model. a Tumor volumes measured by 3D-USG in spheroid-plug and
classical model. b In vivo bioluminescence signal (IVIS) from
spheroid-plug and classical model tumors. Two-way ANOVA with
Bonferroni post-test (*p<0.05, **p<0.01, ***p<0.001) between models
in a given day, n=6–12
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histological analysis, differences between models: its val-
ue was lower in spheroid-plug model, both in B16
(p<0.01) and LLC tumors (p<0.05) (Fig. 3c).
Altogether, the spheroid-plug tumors were less necrotic.
Our analysis showed also that in vivo imaging could be used
to calculate necrosis factor as noninvasive indicator of tumor
necrosis.
Spheroid-plug model ensures stable vascularization
of tumors
Necrotic areas of tumors are often the consequence of inade-
quate and nonfunctional tumor vasculature [15, 16]. We mon-
itored development of vasculature within tumors in vivo (days
1, 7, and 14 after tumor injection) using 3D-USG with
Fig. 3 Lower necrotic content in spheroid-plug tumors. a H&E staining
of necrotic areas within tumors from spheroid-plug model. b Necrosis
factor (NF) estimation of necrotic content in tumors by noninvasive
in vivo imaging and NF correlation with necrotic content in tumors
assessed by H&E staining. c NF in spheroid-plug model in B16 and
LLC tumors. *p<0.05, **p<0.01, Mann–Whitney test
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perfusion analysis. Performed measurements indicated differ-
ent kinetics of tumor angiogenesis between classical and
spheroid-plug model in B16 tumors. While at day 7 we ob-
served a higher perfusion in classical model (17.84±2.31 vs.
9.42±1.74 %, p<0.01) (Fig. 4a), at day 14, it decreased and
was lower than in spheroid model (5.45±1.82 vs. 14.33±
2.35 %, p<0.01) (Fig. 4a). The observed pattern — slower
development of vasculature at day 7 (14.71±1.99 vs. 10.93±
1.82 %) but higher vascularization at day 14 (4.77±0.73 vs.
7.90±0.84 %) in spheroid-plug model compared to classical
model — was also visible in LLC tumors; however, the dif-
ferences did not reach statistical significance (Fig. 4b).
Furthermore, we noticed the difference in vessel localiza-
tion within tumors (Fig. 4c, d). At day 14, in classical model,
vessels were visible only near the tumor borders, whereas in
spheroid-plug model, vessels penetrated the tumor core, as
shown by visualization of 3D-USG analysis (Fig. 4c, d).
Infiltration of cells with progenitor phenotype is increased
in spheroid-plug model
Infiltrating host cells may drive tumor angiogenesis [17, 18].
As spheroid-plug tumors were more vascularized, we checked
if increased vascularization correlates with presence of other
host cells. We took advantage of GFP-expressing tumor cells,
what enabled us to distinguish GFP+ tumor cells from GFP−
infiltrating cells by using flow cytometry (Fig. 5a).
First, we checked the content of endothelial cells. The total
number of endothelial cells with CD45−Sca-1+CD31+c-Kit−
phenotype (Fig. 5a) was significantly higher in the case of
spheroid-plug model than in classical model, both in B16
(1.52±0.55 vs. 0.039±0.009 %, p<0.01) and LLC (0.13±
0.061 vs. 0.083±0.015 %, p<0.05) tumors (Fig. 5b).
Next, among infiltrating cells, we distinguished population
with non-hematopoietic progenitor cell phenotype
CD45−Sca-1+CD31−cKit+ (Fig. 5a). This population was sig-
nificantly increased in spheroid-plug model compared to the
classical model in case of B16 tumors (4.92±1.48 vs. 0.71±
0.36 %, p<0.01), and similar tendency was observed in LLC
tumors (0.067±0.03 vs. 0.012±0.004 %, p=0.16) (Fig. 5c).
Apart from endothelial and mesenchymal cells [19–21],
various hematopoietic progenitors may also regulate angio-
genesis [22, 20, 21]. Indeed, we found that cells with hema-
topoietic progenitor phenotype CD45+Sca-1+c-Kit+ infiltrated
tumors (Fig. 5d). These cells were more abundant in spheroid-
plug model than in classical model in B16 tumors (10.16±
Fig. 4 Development of tumor vasculature in spheroid-plug and classical
model assessed by Doppler 3D-USG analysis. a Vascularization in B16
spheroid-plug and classical model tumors, observed at days 1, 7, and 14. b
Vascularization in LLC tumors observed at days 1, 7, and 14. c, d Visual-
ization of vessels in classical and spheroid-plug model. Two-way ANOVA
with Bonferroni post-test (**p<0.01) between models in a given day
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5.13 vs. 1.51±0.71%, p<0.01) (Fig. 5e). However, in the case
of LLC, there were no differences in the content of hemato-
poietic progenitors between tested models (Fig. 5e).
Taken together, we observed that in B16 tumors, the aug-
mented angiogenesis in spheroid-plug model correlated not
only with higher number of endothelial cells but also with
increased infiltration of cells expressing progenitor markers
(c-Kit and Sca-1). Such relationship seems to be tumor type
specific, as it was not observed in tumors formed by LLC
cells.
Spheroid-plug model increases the number of cells
with cancer stem cell phenotype
In the next step, we compared heterogeneity of tumor cells
between spheroid-plug and classical models. Given that
in vitro 3D spheroid culture facilitates the acquisition of can-
cer stem cell properties [23–25], we wondered if there were
more tumor cells with cancer stem cell phenotype in tested
spheroid-plug model. To verify this hypothesis, we analyzed
expression of several markers on GFP+ tumor cells that were
previously thought to characterize cancer stem cells: c-Kit
[26], Sca-1 [27], CD133 [28–30], CD49f [31], and CXCR4
[30, 32, 33].
The obtained results revealed that most of the LLC and
B16 tumor cells expressed CD49f, what suggests that this
antigen alone did not select unique cancer stem cells in inves-
tigated models (Fig. 6a). Nevertheless, we used CD49f togeth-
er with CXCR4 to analyze heterogeneity of tumor cells
(Fig. 6a). We detected a minor population expressing CXCR4
among LLC and B16 cells, both within CD49f+ and CD49f−
subsets (Fig. 6a). The number of CXCR4+CD49f− tumor cells
Fig. 5 Infiltration of tumors in spheroid-plug and classical model. a
Representative flow cytometry analysis of cells infiltrating tumors. b
Infiltration of endothelial cells in tumors from spheroid-plug and classical
model. c Content of CD45−Sca+CD31−c-Kit+ non-hematopoietic
progenitor cells in spheroid-plug and classical model tumors. d Repre-
sentative flow cytometry analysis of hematopoietic cells infiltrating tu-
mors. e Infiltration of CD45+cKit+Sca-1+ hematopoietic cells within tu-
mors. *p<0.05, **p<0.01, Mann–Whitney test
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was higher in spheroid-plug model than in classical
model either in B16 or LLC tumors (Fig. 6b), while
CXCR4+CD49f+ population was more abundant in
spheroid-plug model only in B16 tumors (Fig. 6c). Ex-
pression of c-Kit, Sca-1, or CD133 did not distinguish
separate populations in B16 tumors. Differently, in LLC
Fig. 6 Analysis of stem cell markers expression in tumors from
spheroid-plug and classical model. aRepresentative flow cytometry anal-
ysis of CXCR4 and CD49f expression on tumor cells. b The
CXCR4+CD49− subpopulation in spheroid-plug model in both B16 and
LLC tumors. c The CXCR4+CD49+ subpopulation—in B16 tumors and
LLC tumors. d, e c-Kit+CD133−Sca-1+ and c-Kit−CD133+Sca-1+ popu-
lation among LLC tumors, **p<0.01 Mann–Whitney test
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tumors, we found c-Kit+CD133− and c-Kit−CD133+ sub-
populations that expressed also Sca-1 (Fig. 6d); howev-
er, there were no differences in content of these subpop-
ulations between tested models (Fig. 6e).
Finally, we tried to explain why some of the described
populations expressing stem cell markers were changed in
spheroid-plug model, while other did not differ. One possibil-
ity is that in vitro spheroid culture itself induces cells with
cancer stem cell phenotype, which then persist during
in vivo tumor development. Flow cytometry analysis con-
firmed that at least part of populations expressing stem cell
markers were induced already by 3D culture conditions
in vitro. We observed that spheroid culture increased frequen-
cy of CXCR4+CD49f+ B16 cells (Supplemental Fig. S3A)
consistently with changes observed in vivo in spheroid-plug
model (Fig. 6c). Similarly, spheroid culture led to increased
number of CXCR4+CD49f− LLC cells (Supplemental
Fig. S3B), in concert to cell profile observed in vivo in
spheroid-plug model (Fig. 6b).
In contrast, in in vitro spheroid culture, we did not detect
CXCR4+CD49f− population in B16 cells as well as
CXCR4+CD49f+ and c-Kit+CD133−Sca-1+ subsets in LLC
cells (data not shown). Moreover, c-Kit−CD133+Sca-1+ pop-
ulation was induced in LLC spheroids in vitro (Supplemental
Fig. S3C), what was not observed in spheroid-plug LLC tu-
mors (Fig. 6e). Thus, the altered frequency of these popula-
tions in vivo in spheroid-plug model cannot be explained by
the changes caused by spheroid formation in vitro.
Spheroid-plug model is suitable for testing the efficacy
of antiangiogenic drugs
To compare the efficacy of known antiangiogenic drug in
classical and spheroid-plug model, we chose axitinib which
is a new type of small molecule tyrosine kinase inhibitor [34]
with evidenced effectiveness in B16 tumor model [35, 36].
The treatment with axitinib was started 7 days after injection
of tumors (Fig. 7a).
Firstly, we compared B16 tumor growth kinetics between
treated and control groups in both models with the use of 3D-
USG. Again, we could observe fast logarithmic growth of
tumor volume in classical model (13.89±1.68-fold increase
at day 21 comparing to day 7 in control group) (Fig. 7b). In
mice dosed with axitinib changes in tumor volume were
smaller (2.08±0.31-fold increase) (Fig. 7b). The fast growth
of tumors in classical model forced us to terminate experiment
at day 21.
In comparison, control tumors from spheroid-plug model
grew slower (2.86±0.92-fold increase at day 21 when com-
paring to day 7), and we were able to prolong experiment till
day 28 (Fig. 7b). Similarly to classical model, we observed
significant difference in tumor volumes between control and
treated groups at the end of experiment (684.6±162.2 mm3 in
control group vs. 64.34±13.56 mm3 in axitinib group,
p<0.0001) (Fig. 7b).
We also monitored tumor development by IVIS. Although
axitinib significantly decreased the size of tumors at the end of
the experiment in both models, there was no significant dif-
ference in IVIS signal in classical model (Fig. 7c).
On the other hand, in spheroid-plug model, the axitinib
treatment not only decreased tumor size but also resulted in
substantial differences in IVIS signal between treated and
non-treated groups (37.01-fold lower signal in axitinib group
at day 28, p<0.01) (Fig. 7c). Additionally, calculated necrosis
factor values showed that axitinib significantly influenced ne-
crosis content only in spheroid-plug model, whereas it had no
effect on tumors in classical model (Fig. 7d).
Axitinib is an antiangiogenic drug; therefore, we evaluated
tumor vascularization as an important parameter reflecting the
drug efficiency. Measurements performed using 3D-USG
with perfusion analysis revealed different effect of axitinib
on tumor vasculature in examined models. Axitinib treatment
had bigger effect on tumors in spheroid-plug approach: treated
tumors were significantly less vascularized than those from
control group (3.18±0.68 vs. 7.47±1.11 % at day 21,
p<0.01; 4.38±1.33 vs. 9.08±0.92 % at day 28, p<0.01)
(Fig. 7e). In contrast, differences between groups in classical
model were smaller and did not reach statistical significance at
the end of experiment (4.5±0.77 % in treated group vs. 6.38±
0.83 % in control at day 21, NS) (Fig. 7e). Consistently, we
observed significantly less endothelial cells (defined by flow
cytometry as CD45−CD31+Sca-1+c-Kit−) after treatment with
axitinib in spheroid-plug model, what was not visible in clas-
sical model (Fig. 7f).
Moreover, we also examined axitinib influence on metas-
tasis occurrence in both models (Fig. 8a). We were able to
Fig. 7 Accuracy of classical and spheroid-plug model in predicting
efficiency of tumor treatment. a Scheme of experiment. b Influence of
axitinib treatment on tumor volumes in classical and spheroid-plug
model. Two-way ANOVA with Bonferroni post-test (**p<0.01,
****p<0.0001) between groups in a given day, n=7–12. c In vivo
bioluminescence signal (IVIS) from treated and untreated tumors in
both models. Two-way ANOVA with Bonferroni post-test (**p<0.01)
between groups in a given day, n=9–12. d NF in classical and spheroid
model after treatment. Mann–Whitney test: classical model, p=0.573;
spheroid-plug model, *p<0.05; n=8–12. e Changes in vascularization
of classical and spheroid-plug tumors after axitinib. Classical model:
two-way ANOVA, *p<0.05 between groups, n=8–12. Spheroid model:
two-way ANOVAwith Bonferroni post-test (** p<0.01) between groups
in a given day, n=7–12. f Frequency of endothelial cells in tumors at the
end of experiments assessed by flow cytometry. Mann–Whitney test:
*p<0.05, n=8–12
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observe that 60 % of spheroids administered subcutaneously
in the control group formed metastasis after 28 days. Axitinib
treatment completely inhibited that process in spheroid-plug
model (Fig. 8b). In classical model, all mice from control
group developed metastasis already after 21 days, but treat-
ment with axitinib showed only 50 % efficacy in metastasis
inhibition (Fig. 8b).
Discussion
In the present study, we describe the novel in vivo tumor
growth model based on subcutaneous delivery of cancer cells
in the form of single spheroid. Although the interest in tumor
spheroids began in the 70s [37], till now, only few reports
described studies on their in vivo application [38, 39]. These
previous works concerned intraperitoneal injections of multi-
ple spheroids and were limited to the characterization of dis-
sected spheroids [38, 39]. In contrast, we proposed subcuta-
neous injection of single spheroid within Matrigel to analyze
tumor growth, vascularization, host cell infiltration, and tumor
cell heterogeneity.
The rationale for injection of single spheroid instead of
suspension of single cells is that single spheroid better imitates
the initial stages of tumor progression (Fig. 9). The tumor
usually develops from one or few transformed cells which
Fig. 8 Metastasis occurrence in
classical and spheroid-plug model
after axitinib treatment. a Organs
without metastasis (upper) and
showing positive bioluminescent
signal (lower) and b comparison
of metastasis occurrence in both
models after axitinib treatment,
n=4–6
Fig. 9 Rationale for the spheroid-plug model
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form primary tumor lesion [40]. In spheroid-plug model, this
primary tumor lesion is mimicked by injection of a single
spheroid in Matrigel suspension, comprising 1,500–3,500
cells (Fig. 9). Oppositely, in classical model, each individual
injected cell may form the tumor lesions, which subsequently
merging together form a bigger tumor mass. Given that num-
ber of injected cells in classical model reaches millions in
some protocols [9], this classical subcutaneous model is sig-
nificantly distinct from current knowledge about initial stages
of tumor development. Therefore, we proposed a spheroid-
plug model as a modification of classical subcutaneous injec-
tion of tumor cells to more accurately reflect mechanisms of
tumor growth.
To our best knowledge, this is the first attempt that relies on
in vitro cultured tumor spheroids combined with in vivo sub-
cutaneous implantation. Our results indicate that the method
which is used to subcutaneously inject cancer cells — either
classical as cell suspension or as spheroid — had impact on
several aspects of tumor development.
First, we showed that growth rate of tumors is slower in the
spheroid-plug model compared to the classical one (Fig. 2a).
The fast growth of tumors after subcutaneous implantation is
regarded as artificial and often limits the proper selection of
experiment end points [7, 9]. Despite injecting small number
of cells (1,500) in suspension, the tumors still grew artificially
fast, indicating that this might be an intrinsic feature of clas-
sical subcutaneous method. Therefore, the slower growth of
spheroid-derived tumors in Matrigel plug may at least partial-
ly surmount this limitation of subcutaneous models. This abil-
ity to prolong the course of study is particularly important
when the effects of tested drugs or therapies require longer
time to occur. An example of such therapies may be immuno-
therapies which need time to stimulate immunological
responses [41, 42].
Not only is the tumor growth rate affected in spheroid-plug
model but also the necrosis content differs. The smaller size of
tumors correlates with smaller necrosis in spheroid-plug mod-
el comparing to classical model (Fig. 3). Both tumor size and
necrosis content correlate with stage and prognosis of many
tumors [43, 44]. Taken together, smaller size and lower necro-
sis content indicate that spheroid-plug tumors mimicked less
advanced stage than tumors from classical models.
Next, we observed that development of tumor vasculariza-
tion follows distinct patterns in classical and spheroid-plug
model, especially in B16 tumors (Fig. 4a, b). In classical mod-
el, vascularization of tumors reached highest values already at
day 7 and then significantly dropped at day 14. Oppo-
sitely, in the spheroid-plug model, tumor angiogenesis
progressed slower and the vascularization at day 7 was
lower than in classical model but sustained or even
increased (in B16 tumors) at day 14.
Tumor angiogenesis is an important target of currently be-
ing developed anticancer strategies [45]. However, many
studies demonstrating efficacy of antiangiogenic drugs in an-
imal subcutaneousmodels were not confirmed in clinical trials
[46, 47]. Our analysis demonstrated that tumor vascularization
develops differently in spheroid-plug model comparing to
classical subcutaneous implantation. Given that the tumor an-
giogenesis differs between the models, it is justified to sup-
pose that outcome of antiangiogenic drugs tests may depend
on model used in such studies.
Along with targeting tumor angiogenesis, new anticancer
treatments focus also on regulating the infiltration of host cells
[18, 20]. Different progenitors of non-hematopoietic and he-
matopoietic origin infiltrate tumor and may facilitate tumor
growth [19, 21]. On the other hand, the potential to infiltrate
tumors may be also used as a tool to deliver therapeutic genes
into tumors [48–51]. We tested if the spheroid-plug model
could be used to study tumor infiltration by the host cells.
B16 tumors from spheroid-plug model were more infiltrated
by hematopoietic and non-hematopoietic cells with progenitor
phenotype. Increased infiltration of tumors by progenitor cells
makes the spheroid-plug model a valuable tool to study this
phenomenon.
Next, we addressed the aspects of heterogeneity of tumor
cells in spheroid-plug model with focus on cells with cancer
stem cell phenotype. We evaluated expression of several
markers shown before to characterize cancer stem cells. Con-
sistently with previous reports [33, 52], we were able to dis-
tinguish among both LLC and B16 tumor minor subpopula-
tions with CXCR4 expression that is thought to characterize
cancer stem cells. Additionally, we showed that CXCR4+ frac-
tion could be further divided based on CD49f expression,
what to our best knowledge was not shown before. However,
if expression or lack of expression of CD49f enriches the
CXCR4+ population for functional cancer stem cells needs
to be further elucidated.
It is known that in vitro culture of tumor cells in form of 3D
spheroids changes their phenotype and increases heterogene-
ity among tumor cells, including induction of stem cell phe-
notype [23, 24, 53, 54]. Indeed, we showed that some of the
cancer stem cell populations upregulated in vivo in spheroid-
plug model tumors are already induced by in vitro spheroid
culture (CXCR4+CD49f− in LLC and CXCR4+CD49f+ in
B16, Supplemental Fig. S3). Nevertheless, other tumor popu-
lations with stem cell markers (CXCR4+CD49f− in B16 and
CXCR4+CD49f+, c-Kit−CD133+Sca-1+, c-Kit+CD133−Sca-
1+ in LLC) detected in vivo in spheroid-plug model cannot
be simply linked with induction of these populations by
in vitro 3D conditions, as they were either not detected or were
differentially regulated by in vitro spheroid culture. Therefore,
increased heterogeneity among tumor cells observed in
spheroid-plug model at least partially seems to be a result of
different characteristic of tumor growth in vivo. This makes
spheroid-plug model a valuable tool to study tumor heteroge-
neity and cancer stem cells.
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In the present study, we used two different cell lines:
B16F10 and LLC. Spheroid-plug model could be applied to
other tumor cell lines as long as they are capable of forming
spheroids in vitro. It should be tested if the spheroids are
compact enough to sustain their structure during injection.
We evaluated other cancer cells lines and found that tumor
cell lines form spheroids easily (e.g., SMS-CTR and
CW9019 rhabdomyosarcoma, data not shown). However,
there were tumor cell lines which formed clumps of cells
instead of solid spheroids (e.g., squamous cell carcinoma
SSC-VII). This limitation can be overcome by mixing tumor
cells with other cells (we checked fibroblasts or cultured mes-
enchymal stem cells, data not shown), as suggested by
Augustin and co-workers [55]. Such co-spheroids are more
compact and could be injected subcutaneously with the de-
scribed method.
Though the tumor cell line forms spheroids, the difference
between spheroid-plug model and classical model may be
stronger or weaker depending on given tumor cell line. We
suppose that higher growth rate as well as dependence on
vascularization and cancer stem cells may result in bigger
impact of spheroid-plug model on tumor growth in compari-
son to classical method. In our work, the differences between
models are best visible in case of B16 cells, while in case of
LLC they were less evident and sometimes reached only bor-
derline statistical significance. This could be linked with much
higher tumor growth rate of B16 tumors in comparison to
LLC tumors (1,268±263.4 vs. 181.3±20.7 mm3, p<0.001,
at day 14 in classical models, Fig. 2a). Nevertheless, the
course of changes associated with spheroid-plug model was
the same in B16 and LLC tumors.
Additionally, we postulated that simultaneous measure-
ment of tumor volume with IVIS analysis may be used to
estimate tumor necrosis (Fig. 3b), by calculating NF. Al-
though the proposed necrosis factor cannot replace histologi-
cal analysis, it may be applied as an approximate determinant
of tumor necrosis that can be monitored by noninvasive
in vivo imaging.
Finally, to validate the proposed spheroid-plug model as a
tool for drug testing, we compared the efficacy of a known
antiangiogenic agent in classical and spheroid-plug model. To
this aim, we chose axitinib, a small molecule inhibitor of vas-
cular endothelial growth factor receptors 1–3, platelet-derived
growth factor receptor, and stem cell growth factor receptor c-
Kit [34]. This potent drug gained FDA approval for treatment
of advanced renal cell carcinoma in 2012 [56] and it is still
tested for other types of cancer. Moreover, axitinib was al-
ready evaluated in murine melanoma models where it has
proven its efficacy either alone [36] or with combination with
other therapies [35, 57] and continues to be assessed for mel-
anoma treatment in clinical trials [58, 59].
We observed differences in effects of axitinib treatment in
compared models. Although axitinib inhibited tumor growth
both in classical and spheroid-plug model (Fig. 7b), the cal-
culated necrosis factor indicated that axitinib decreases the
viability of tumor cells only in spheroid-plug model
(Fig. 7d). The potential of axitinib to reduce vascularization
of tumors was better visible in spheroid-plug model than in
classical approach (Fig. 7e, f). Given the knownmechanism of
axitinib action [36], it could be expected that axitinib should
decrease vascularization and cause necrosis—explaining the
best visible effect in spheroid-plug model. Therefore, this
work not only shows the suitability of spheroid-plug model
to test antiangiogenic drugs but also its advantages over the
classical model in term of drug effectiveness.
Spheroid-plug model could also be used to study metasta-
sis of tumor cells. While the frequency of metastasis is lower
than in the classical model, axitinib completely abolished me-
tastasis in spheroid-plug model. These results are in accor-
dance with already published studies about axitinib influence
on inhibiting melanoma metastasis [36].
Altogether, spheroid-plug model affects kinetics of
tumor growth rate, necrosis content, vascularization of
tumors, infiltration by progenitor cells, and presence of
cancer cells with stem cell phenotype. These are the
crucial aspects of tumor development that are investigat-
ed nowadays as a possible targets of therapeutic inter-
vention. Without burdensome modifications of classical
subcutaneous model, the spheroid-plug model allows
studying tumors that develop differentially to classical
subcutaneous methods regarding important tumor deter-
minants. The spheroid-plug model could be an alterna-
tive to classical approach for antiangiogenic drug
screening as it showed advantages over classical model
in testing an already evaluated compound. Nevertheless,
studies including antitumor therapy testing combined
with comparison to clinical data are needed to further
verify whether spheroid-plug model better reflects the
complexity of tumor development and consequently if
it is reliable for drug screening.
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